Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Ayyappan · SciRah

Researcher profile · Semantic Scholar

S. Ayyappan

Share profile

S. Ayyappan — researcher profile on SciRah

h-index: 16
Works: 87
Citations: 859

Most-cited papers

Kidney Disease among Patients with Sickle Cell Disease, Hemoglobin SS and SC.
P. Drawz, S. Ayyappan, M. Nouraie, Santosh L. Saraf +4 more
2016American Society of Nephrology. Clinical Journal98 citations Open access
Semantic Scholar
Incidence and survival of hematological cancers among adults ages ≥75 years
J. Krok-Schoen, J. Fisher, J. Stephens, Alice S. Mims +3 more
2018Cancer Medicine76 citations Open access
Semantic Scholar
Imaging of musculoskeletal manifestations in sickle cell disease patients.
Vijaya Kosaraju, Alok Harwani, S. Partovi, Nicholas Bhojwani +4 more
2017British Journal of Radiology63 citations Open access
Semantic Scholar
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial
W. Kim, Tae Min Kim, Seok-Goo Cho, I. Jarque +126 more
2025Nature Cancer60 citations Open access
Semantic Scholar
Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
S. Ayyappan, W. Kim, Tae Min Kim, J. Walewski +21 more
2023Blood48 citations Open access
Semantic Scholar
Epidermal growth factor receptor (EGFR)-targeted therapies in esophagogastric cancer.
S. Ayyappan, D. Prabhakar, N. Sharma
2013Anticancer Research46 citations
Semantic Scholar
Novel and emerging therapies for B cell lymphoma
S. Ayyappan, K. Maddocks
2019Journal of Hematology & Oncology42 citations Open access
Semantic Scholar
Defining primary refractory large B-cell lymphoma
Allison M. Bock, Raphael Mwangi, Yu-Cai Wang, A. Khurana +16 more
2024Blood Advances31 citations Open access
Semantic Scholar
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma
J. Alderuccio, L. Arcaini, M. Watkins, A. Beaven +34 more
2022Blood Advances30 citations Open access
Semantic Scholar
Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
W. Kim, Tae Min Kim, Seok-Goo Cho, I. Jarque +16 more
2022Blood27 citations Open access
Semantic Scholar
T cell help in the tumor microenvironment enhances rituximab-mediated NK cell ADCC.
Jyoti Arora, S. Ayyappan, Chao-Bo Yin, Brian J. Smith +4 more
2024Blood26 citations Open access
Semantic Scholar
Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma ‐ specific venous thrombosis prediction models
G. Dharmavaram, S. Cao, S. Sundaram, S. Ayyappan +11 more
2020American journal of hematology/oncology23 citations Open access
Semantic Scholar
Characteristics and outcomes of progressive multifocal leukoencephalopathy in hematologic malignancies and stem cell transplant – a case series
D. Adrianzen Herrera, S. Ayyappan, Sakshi Jasra, N. Kornblum +6 more
2018Leukemia and Lymphoma20 citations
Semantic Scholar
Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes
Charlotte B Wagner, K. Boucher, A. Nedved, I. Micallef +26 more
2023Haematologica19 citations Open access
Semantic Scholar
Resistance mechanism for ibrutinib in marginal zone lymphoma.
N. Epperla, A. Shanaah, Dan A. Jones, B. Christian +3 more
2019Blood Advances16 citations Open access
Semantic Scholar
Marginal Zone Lymphoma: Clinicopathologic Variations and Approaches to Therapy
S. Ayyappan, B. William
2018Current Oncology Reports16 citations
Semantic Scholar
Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers
T. Voorhees, E. McLaughlin, P. Torka, Jorge A. Florindez +22 more
2025Blood Cancer Journal15 citations Open access
Semantic Scholar
Ruxolitinib Plus Nivolumab in Patients with R/R Hodgkin Lymphoma after Failure of Check-Point Inhibitors: Preliminary Report on Safety and Efficacy
V. Bachanova, Livia Hegerova, Q. Cao, Murali Janakiram +6 more
2021Blood12 citations Open access
Semantic Scholar
Type 1 (11; 22)(q24: q12) translocation is common in Ewing’s sarcoma/ peripheral neuroectodermal tumour in south Indian patients
T. Parija, S. Shirley, S. Uma, Kamalalayam Raghavan Rajalekshmy +2 more
2005Journal of Biosciences12 citations
Semantic Scholar
Prospective Nonrandomized Comparative Study of Laparoscopic Versus Open Surgical Staging for Endometrial Cancer in India
P. AnsarP, S. Ayyappan, V. Mahajan
2018Indian Journal of Surgical Oncology11 citations Open access
Semantic Scholar
Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study
Allison M. Bock, J. Gile, M. Larson, K. Poonsombudlert +15 more
2023Blood Cancer Journal10 citations Open access
Semantic Scholar
Lung cancer in the very elderly: incidence, presentation, and diagnostic decision-making. A retrospective analysis at a teaching community hospital
S. Ayyappan, C. González, Roopa Yarlagadda, Y. Zakharia +1 more
2011Journal of Community Hospital Internal Medicine Perspectives9 citations Open access
Semantic Scholar
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma
Yu-Cai Wang, M. Larson, Steven R. Hwang, D. Villa +52 more
2025Blood Advances8 citations Open access
Semantic Scholar
Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy
Yucai Wang, M. Larson, Steven R. Hwang, Anita Kumar +52 more
2023Blood8 citations Open access
Semantic Scholar
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study
N. Epperla, Qiu-Hong Zhao, S. Chowdhury, L. Shea +41 more
2022Journal of Hematology & Oncology8 citations Open access
Semantic Scholar
ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM‐2
M. Poon, J. Walewski, T. Kim, S. Cho +16 more
2023Hematological Oncology7 citations Open access
Semantic Scholar
Retrospective study of the incidence and patterns of arterial and venous thrombosis in Chinese versus African American patients with multiple myeloma
R. Raghupathy, S. Ayyappan, D. Prabhakar, E. Campagnaro +5 more
2017British Journal of Haematology7 citations Open access
Semantic Scholar
Viral co-infections and paraproteins in HIV: effect on development of hematological malignancies
Erin Jou, O. Gligich, A. C. Y. Chan, D. Mohan +6 more
2016Annals of Hematology7 citations Open access
Semantic Scholar
Risk factors for cardiovascular events and mortality in patients diagnosed with diffuse large B‐cell lymphoma and treated with anthracyclines
Akiva Diamond, S. Ayyappan, S. Cao, N. Tashtish +4 more
2022Hematological Oncology6 citations
Semantic Scholar
Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial
B. William, Ying Huang, A. Johnson, J. Brammer +12 more
2019Blood6 citations Open access
Semantic Scholar
Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma.
L. Nastoupil, Clark R. Andersen, Amy A. Ayers, Yucai Wang +28 more
2024Clinical Lymphoma, Myeloma & Leukemia5 citations Open access
Semantic Scholar
A Rare Case of Midostaurin-Associated Sweet's Syndrome
Hesham A. Yasin, Tessa Laytem, G. Sutamtewagul, S. Ayyappan
2022Case Reports in Hematology5 citations Open access
Semantic Scholar
Postibrutinib relapse outcomes for patients with marginal zone lymphoma
N. Epperla, Qiu-Hong Zhao, S. Chowdhury, Lauren K. Shea +42 more
2022Blood Advances5 citations Open access
Semantic Scholar
Technique of Laparoscopic Hysterectomy and Pelvic Lymphadenectomy for Endometrial Cancer
A. Pookunju, S. Ayyappan
2018Indian Journal of Surgical Oncology5 citations Open access
Semantic Scholar
Retrospective study of the prevalence and progression of monoclonal gammopathy in HIV positive versus HIV negative patients
Erin Jou, O. Gligich, A. C. Y. Chan, D. Mohan +6 more
2017Hematological Oncology5 citations Open access
Semantic Scholar
The Broken Pen Penalty
Umashankar Lakshmanadoss, S. Ayyappan, Akshay B. Jain, Marilyn Konezny +1 more
2010Diabetes Technology & Therapeutics5 citations
Semantic Scholar
P1115: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2
J. Walewski, Tae Min Kim, Seok-Goo Cho, I. Jarque +16 more
2023HemaSphere4 citations Open access
Semantic Scholar
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
V. Bachanova, J. Zak, Q. Cao, J. Maakaron +9 more
2023Hematological Oncology4 citations Open access
Semantic Scholar
Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study
E. Iskierka-Jażdżewska, W. Kim, Seok-Goo Cho, Tae Min Kim +23 more
2023Blood4 citations Open access
Semantic Scholar
Wearable Monitors Facilitate Exercise in Adult and Pediatric Stem Cell Transplant
Ethan Pottebaum, Alexa Warmoth, S. Ayyappan, David S. Dickens +5 more
2021Exercise and sport sciences reviews4 citations Open access
Semantic Scholar
Cardiovascular Toxicity after Therapy for Diffuse Large B Cell Lymphoma Occurs Early and Results in Decreased Overall Survival.
S. Ayyappan, Akiva Diamond, Vinita Gupta, B. Cooper +7 more
20164 citations
Semantic Scholar
Renal Disease in Sickle Cell: Clinically Varied and Associated with Increased Mortality
S. Ayyappan, P. Drawz, M. Nouraie, M. Hildesheim +5 more
20124 citations
Semantic Scholar
Current and emerging therapies in primary myelofibrosis.
S. Ayyappan, Murali Janakiram, R. Raghupathy
2012Cardiovascular & Haematological Disorders - Drug Targets4 citations
Semantic Scholar
Squamous cell carcinoma of ascending colon. A case study.
M. Ganesh, S. Ayyappan, U. Majhi
1999Indian Journal of Cancer4 citations
Semantic Scholar
Treatment Duration and Risk of Fatal Infections in Patients with B-Cell Non-Hodgkin Lymphoma Achieving Complete Response with Odronextamab
G. von Keudell, Eliza A. Hawkes, C. Carpio, Max S. Topp +8 more
2024Blood3 citations
Semantic Scholar
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
A. Bock, R. Mwangi, Y. Wang, A. Khurana +15 more
2023Hematological Oncology3 citations Open access
Semantic Scholar
Development of a Risk Score for Cardiovascular Events in Anthracycline Treated DLBCL Patients
Akiva Diamond, S. Ayyappan, S. Cao, N. Tashtish +4 more
2021Blood3 citations Open access
Semantic Scholar
Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
B. Christian, Ying Huang, S. Ayyappan, R. Baiocchi +7 more
2019Blood3 citations
Semantic Scholar
Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial
W. Kim, Tae Min Kim, Seok-Goo Cho, I. Jarque +126 more
2025Nature Cancer2 citations Open access
Semantic Scholar
Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma.
Yu-Cai Wang, M. Larson, Anita Kumar, Brian T. Hill +16 more
2024Journal of Clinical Oncology2 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Ambati×8
Invite
S. Ambati — researcher profile on SciRah
I. Jarque×7
Invite
I. Jarque — researcher profile on SciRah
E. Iskierka-Jażdżewska×7
Invite
E. Iskierka-Jażdżewska — researcher profile on SciRah
H. Prince×7
Invite
H. Prince — researcher profile on SciRah

×7

Invite

A. Chaudhry — researcher profile on SciRah

Invite

H. Mohamed — researcher profile on SciRah

Invite

N. Epperla — researcher profile on SciRah

Invite

C. Carpio — researcher profile on SciRah

Invite

M. Ufkin — researcher profile on SciRah

Invite

K. Maddocks — researcher profile on SciRah

Jonathon B. Cohen×6

Invite

Jonathon B. Cohen — researcher profile on SciRah

Invite

P. Caimi — researcher profile on SciRah